CIHR-IMHA Dialogue Series
EURO-NMD Neuropathology Webinar Series | Ep 3: Nerve Biopsy in Clinical Practice
19th UK Neuromuscular Translational Research Conference 2026
CIHR-IMHA Dialogue Series
CIHR-IMHA Dialogue Series
CPD-Accredited Webinar | Emerging Insights Into AAV‑Mediated Gene Therapy: Understanding Hepatotoxicity and Implications for Neuromuscular Disorders
NMD4C are MDC are pleased to invite you to a CPD-accredited webinar on Emerging Insights Into AAV‑Mediated Gene Therapy: Understanding Hepatotoxicity and Implications for Neuromuscular Disorders. This CPD-accredited webinar is primarily targeted at Canadian clinicians, academics and trainees with an interest in neuromuscular diseases. NMD4C and MDC are providing organizational and technical support. This is an independent clinical/academic webinar with no industry sponsorship or influence.
Speakers:
- Dr. James Dowling (Chair): Clinical safety signals and efficacy of AAV gene therapy in neuromuscular disorders
- Dr. Emanuela Pannia: Preclinical models and mechanisms of AAV-associated hepatotoxicity: lessons learned from X-linked myotubular myopathy.
Details:
- Date: Tuesday, May 5, 2026
- Time: 5-6 pm ET
Learning Objectives:
- Summarize the current safety profile and efficacy of AAV-based gene therapies in neuromuscular disorders.
- Describe potential mechanisms underlying AAV-associated liver toxicity.
- Understand current biomarkers and strategies for monitoring, mitigating, and managing adverse events.
- Discuss critical considerations in preclinical development and clinical translation of emerging gene therapies.
The NMD Rounds & Educational Webinars are self-approved group learning activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
If you have any questions, please contact our Network Manger, Erin Beattie